gdc-0449 and Melanoma

gdc-0449 has been researched along with Melanoma* in 2 studies

Reviews

1 review(s) available for gdc-0449 and Melanoma

ArticleYear
Dermatology update: The dawn of targeted treatment.
    Cleveland Clinic journal of medicine, 2015, Volume: 82, Issue:5

    During the past several years, targeted therapies have significantly improved outcomes in advanced basal cell carcinoma, psoriasis, and metastatic melanoma. This article reviews how advances in our understanding of the molecular pathogenesis of these diseases led to the development of targeted therapies and how these therapies are improving outcomes. Research is ongoing to address continuing challenges of drug resistance, adverse effects, and how best to use the new medications.

    Topics: Adult; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azetidines; Brain Neoplasms; Carcinoma, Basal Cell; Dermatologic Agents; Dermatology; Etanercept; Female; Humans; Imidazoles; Indoles; Interleukin-17; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Oximes; Piperidines; Proto-Oncogene Proteins B-raf; Psoriasis; Pyridines; Pyridones; Pyrimidinones; Skin Neoplasms; Sulfonamides; Tumor Necrosis Factor-alpha; Ustekinumab; Vemurafenib

2015

Other Studies

1 other study(ies) available for gdc-0449 and Melanoma

ArticleYear
Fast growing melanoma following treatment with vismodegib for locally advanced basal cell carcinomas: report of two cases.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 91

    Topics: Aged, 80 and over; Anilides; Antineoplastic Agents; Carcinoma, Basal Cell; Cell Proliferation; Fatal Outcome; Female; Humans; Male; Melanoma; Pyridines; Risk Factors; Skin Neoplasms; Time Factors; Treatment Outcome; Tumor Burden

2018